COVID-19-Associated Fulminant Myocarditis: Pathophysiology-Related Phenotypic Variance
- PMID: 35863847
- PMCID: PMC9535030
- DOI: 10.1016/j.jacc.2022.06.003
COVID-19-Associated Fulminant Myocarditis: Pathophysiology-Related Phenotypic Variance
Keywords: COVID-19; SARS-CoV-2; cardiomyopathy; myocarditis.
Conflict of interest statement
Funding Support and Author Disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Comment on
-
Phenotypic Heterogeneity of Fulminant COVID-19--Related Myocarditis in Adults.J Am Coll Cardiol. 2022 Jul 26;80(4):299-312. doi: 10.1016/j.jacc.2022.04.056. J Am Coll Cardiol. 2022. PMID: 35863846 Free PMC article.
References
-
- Writing C., Gluckman T.J., Bhave N.M., et al. 2022 ACC expert consensus decision pathway on cardiovascular sequelae of COVID-19 in adults: myocarditis and other myocardial involvement, post-acute sequelae of SARS-CoV-2 infection, and return to play: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2022;79:1717–1756. - PMC - PubMed
-
- Kociol R.D., Cooper L.T., Fang J.C., et al. Recognition and initial management of fulminant myocarditis: a scientific statement From the American Heart Association. Circulation. 2020;141:e69–e92. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
